|
Gene: RFX5 |
Gene summary for RFX5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RFX5 | Gene ID | 5993 |
Gene name | regulatory factor X5 | |
Gene Alias | RFX5 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P48382 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5993 | RFX5 | LZE2T | Human | Esophagus | ESCC | 2.66e-02 | 2.87e-01 | 0.082 |
5993 | RFX5 | LZE8T | Human | Esophagus | ESCC | 2.33e-07 | 1.36e-01 | 0.067 |
5993 | RFX5 | LZE24T | Human | Esophagus | ESCC | 1.37e-14 | 3.39e-01 | 0.0596 |
5993 | RFX5 | LZE6T | Human | Esophagus | ESCC | 2.96e-04 | 2.20e-01 | 0.0845 |
5993 | RFX5 | P1T-E | Human | Esophagus | ESCC | 1.79e-03 | 1.28e-01 | 0.0875 |
5993 | RFX5 | P2T-E | Human | Esophagus | ESCC | 7.68e-41 | 6.14e-01 | 0.1177 |
5993 | RFX5 | P4T-E | Human | Esophagus | ESCC | 9.60e-08 | 3.95e-01 | 0.1323 |
5993 | RFX5 | P5T-E | Human | Esophagus | ESCC | 7.29e-04 | 6.08e-02 | 0.1327 |
5993 | RFX5 | P8T-E | Human | Esophagus | ESCC | 1.05e-06 | 9.91e-02 | 0.0889 |
5993 | RFX5 | P9T-E | Human | Esophagus | ESCC | 5.36e-16 | 2.80e-01 | 0.1131 |
5993 | RFX5 | P10T-E | Human | Esophagus | ESCC | 8.45e-09 | 1.39e-01 | 0.116 |
5993 | RFX5 | P11T-E | Human | Esophagus | ESCC | 2.38e-07 | 2.32e-01 | 0.1426 |
5993 | RFX5 | P12T-E | Human | Esophagus | ESCC | 1.14e-08 | 2.25e-01 | 0.1122 |
5993 | RFX5 | P15T-E | Human | Esophagus | ESCC | 4.12e-18 | 3.77e-01 | 0.1149 |
5993 | RFX5 | P16T-E | Human | Esophagus | ESCC | 5.07e-22 | 2.55e-01 | 0.1153 |
5993 | RFX5 | P17T-E | Human | Esophagus | ESCC | 6.06e-05 | 3.39e-01 | 0.1278 |
5993 | RFX5 | P19T-E | Human | Esophagus | ESCC | 2.03e-02 | 2.38e-01 | 0.1662 |
5993 | RFX5 | P20T-E | Human | Esophagus | ESCC | 4.40e-11 | 3.04e-01 | 0.1124 |
5993 | RFX5 | P21T-E | Human | Esophagus | ESCC | 2.47e-15 | 3.76e-01 | 0.1617 |
5993 | RFX5 | P22T-E | Human | Esophagus | ESCC | 1.42e-10 | 1.97e-01 | 0.1236 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa0461230 | Esophagus | ESCC | Antigen processing and presentation | 51/4205 | 78/8465 | 3.57e-03 | 9.34e-03 | 4.78e-03 | 51 |
hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa04612114 | Esophagus | ESCC | Antigen processing and presentation | 51/4205 | 78/8465 | 3.57e-03 | 9.34e-03 | 4.78e-03 | 51 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0461229 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa04612113 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa04612210 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515221 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
hsa0461237 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515231 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RFX5 | SNV | Missense_Mutation | c.1006G>A | p.Ala336Thr | p.A336T | P48382 | protein_coding | tolerated_low_confidence(0.3) | benign(0.005) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RFX5 | SNV | Missense_Mutation | rs778751859 | c.1403G>A | p.Arg468His | p.R468H | P48382 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RFX5 | SNV | Missense_Mutation | c.1828N>T | p.Asp610Tyr | p.D610Y | P48382 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.97) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RFX5 | SNV | Missense_Mutation | c.190N>A | p.Leu64Ile | p.L64I | P48382 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
RFX5 | SNV | Missense_Mutation | rs771641554 | c.116N>T | p.Ser39Phe | p.S39F | P48382 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RFX5 | SNV | Missense_Mutation | novel | c.1836N>C | p.Lys612Asn | p.K612N | P48382 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.715) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
RFX5 | SNV | Missense_Mutation | novel | c.1780G>T | p.Asp594Tyr | p.D594Y | P48382 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.733) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RFX5 | SNV | Missense_Mutation | rs778751859 | c.1403G>A | p.Arg468His | p.R468H | P48382 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RFX5 | SNV | Missense_Mutation | rs777652681 | c.881G>A | p.Arg294Gln | p.R294Q | P48382 | protein_coding | tolerated_low_confidence(0.08) | benign(0.435) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RFX5 | SNV | Missense_Mutation | c.1368G>T | p.Glu456Asp | p.E456D | P48382 | protein_coding | tolerated_low_confidence(0.05) | benign(0.001) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |